Northwest Biotherapeutics, Inc (OTC:NWBO) has been moving up since last Friday. Yesterday, the stock added another 
14.33% to its price, while its traded volume hit 1.4 million shares. Now it’s interesting if the climb will continue.
Historical records show that NWBO has not released any news on its business since the end of February and currently no one is informed on its operations. The only publication on the company turns out to be a promotional release by seekingalpha.com which came out last week.
The release featured the challenges of cell-based cancer immunotherapy related to NWBO, though the report was able to pump up the stock price for a day only. After that the gain was broken.
Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. In end-February, the company announced it was going to present at the Cancer Immunotherapy Conference. However, since then no updates on NWBO have been released.
As of September 30, 2011 the company’s cash has increased, though its liabilities also rose up. Apart from these, the stockholders’ deficit and the accumulated deficit of Northwest jumped up.[BANNER]
NWBO has experienced recurring losses from operations and as of end-September last year the company had a working capital deficit of $44.3 million, and a deficit accumulated during the past 15 years of its operations totaling $239.2 million.
The management of Northwest claim that they intend to seek additional financing in the near term. However, there can be no assurance that external sources of financing, including the issuance of notes payable or equity securities, will be available at times and at terms acceptable to them.
